PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas

Rhea-AI Summary

PerturbAI emerged from stealth on March 17, 2026, releasing the world's largest in vivo CRISPR atlas: an 8 million–cell, brain-wide dataset generated with NVIDIA, Allen Institute for Brain Science, and 10x Genomics (Nasdaq: TXG).

The atlas maps thousands of genetic perturbations across hundreds of neuronal cell types, enabling organism-level, circuit-resolved causal genomics and AI-driven therapeutic discovery. PerturbAI closed an oversubscribed pre-seed round in Q3 2025.

Positive

• 8 million cells dataset maps thousands of genetic perturbations
• Collaborations with NVIDIA, Allen Institute, and 10x Genomics (TXG)
• Oversubscribed pre-seed round closed in Q3 2025

Negative

• None.

News Market Reaction – TXG

+8.39%

40 alerts

+8.39% Session close to close

+4.5% Peak in 6 hr 3 min

$2.32B Market Cap

0.8x Rel. Volume

In the Mar 17 session, TXG gained 8.39%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.4% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.4% in the session following this news. A strong positive reaction aligns with the strategic importance of large-scale in vivo CRISPR and single-cell datasets for TXG’s ecosystem. The article highlights collaboration with 10x Genomics on an 8 million-cell brain-wide atlas, reinforcing the value of its platforms in cutting-edge genomics and AI research. Historically, however, at least one AI-related partnership coincided with a negative move, suggesting that enthusiasm around innovation has not always translated into sustained strength.

Key Figures

CRISPR atlas size: 8 million brain-wide cells

1 metrics

CRISPR atlas size 8 million brain-wide cells In vivo CRISPR atlas dataset released with collaborators

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 19	Conference participation	Neutral	-1.6%	Announced fireside chat at TD Cowen health care conference with webcast access.
Feb 12	Earnings results	Positive	+3.5%	Reported Q4 and FY2025 results with narrowed losses and 2026 revenue guidance.
Feb 04	AI partnership	Positive	-1.1%	Announced PharosAI partnership to build a large multimodal cancer dataset on Xenium.
Jan 22	Earnings date set	Neutral	-3.5%	Scheduled Q4 and FY2025 earnings release and investor webcast details.
Jan 15	Reverse stock split	Neutral	+1.3%	Amcor completed 1-for-5 reverse split; operational for trading on Jan 16.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: earnings and some neutral items aligned with modest gains or declines, while at least one positive AI/data collaboration saw a negative price reaction.

Recent Company History

Over the last few months, TXG news included conference participation on Feb 19, 2026, Q4 and full-year 2025 earnings on Feb 12, 2026, and an AI-focused cancer research partnership on Feb 4, 2026. An earnings-date notice on Jan 22, 2026 and an unrelated reverse split for Amcor on Jan 15, 2026 round out the set. Positive, fundamentals-driven news (earnings) aligned with gains, while AI/data collaborations sometimes coincided with mild selloffs, indicating inconsistent trading responses to innovation-oriented headlines.

Key Terms

crisper, in vivo, perturb-seq, genome engineering, +2 more

6 terms

crisper medical

"public release of the world's largest in vivo CRISPR atlas."

A type of gene‑editing technology that lets scientists precisely change DNA sequences inside living cells, like using a pair of molecular scissors guided by a map to cut and replace specific paragraphs in a huge instruction manual. Investors care because it underpins a wave of potential new therapies and biotech products, and progress or setbacks in safety, regulation, or clinical results can rapidly affect the value of companies developing related treatments.

in vivo medical

"Unlike traditional in vitro or single-organ systems, PerturbAI's in vivo CRISPR (Perturb-seq) platform"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

perturb-seq medical

"PerturbAI's in vivo CRISPR (Perturb-seq) platform measures gene function within intact organs"

Perturb-seq is a laboratory method that combines targeted gene edits with single-cell gene-expression reading to see how changing specific genes alters cell behavior. Think of it like flipping individual switches in thousands of rooms and then measuring which lights change—this reveals cause-and-effect links between genes and cellular responses. For investors, it matters because it helps biotech teams validate drug targets, prioritize programs, and reduce late-stage risk by showing which interventions produce the desired molecular effects.

genome engineering medical

"best-in-class technology and deep expertise in genome engineering and AI"

Genome engineering is the deliberate editing of an organism’s DNA to add, remove or change specific genetic instructions—like correcting typos in a recipe or swapping a paragraph in an instruction manual. For investors, it matters because these edits can create new medicines, crops or industrial processes, driving potential revenue, patent value and regulatory risk; success or failure in development and approval can substantially affect a biotech company’s prospects.

genomics medical

"deep expertise spanning CRISPR, genomics, and machine learning"

The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.

causal genomics medical

"organism-level, circuit-resolved, causal genomics."

Causal genomics is the study of which genes or genetic changes actually cause a trait or disease, not just which ones are associated with it. Think of it as a detective process that separates true drivers from bystanders; for investors this helps prioritize which biological targets are most likely to produce effective drugs, diagnostics or therapies and reduces scientific and commercial risk when assessing biotech opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient -

- Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -

SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in vivo CRISPR atlas. The 8 million-cell, brain-wide dataset represents the largest known causal genomics resource generated directly in living tissue.

Unlike traditional in vitro or single-organ systems, PerturbAI's in vivo CRISPR (Perturb-seq) platform measures gene function within intact organs, capturing real biological circuitry rather than isolated cell states. Today's release establishes a new category of biological data: organism-level, circuit-resolved, causal genomics.

"The public release of this CRISPR atlas marks a foundational change for biology," said Xin Jin, Ph.D., co-founder of PerturbAI. "For the first time, we can measure gene function directly inside intact biological systems at a massive scale. This enables systems-level understanding of disease and allows us to model and simulate therapeutic interventions before committing to expensive downstream drug development."

PerturbAI is utilizing its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics for complex metabolic and chronic diseases.

"Given our team's deep expertise spanning CRISPR, genomics, and machine learning, we are uniquely qualified to optimize the application of vivo CRISPR and new AI models to novel therapeutic discovery, making it more scalable, translatable and cost-efficient," said Grace Zheng, Ph.D., co-founder and CEO of PerturbAI.

PerturbAI collaborated with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics (Nasdaq: TXG) to generate and analyze the atlas, which enables systematic evaluation of the brain genome, providing a framework to distinguish causal mechanisms from context-dependent modifiers of disease risk and progression. Specifically, the dataset maps the effects of thousands of genetic perturbations across 8 million cells spanning hundreds of bona fide neuronal cell types in the mouse brain, revealing, among other findings, that the same gene can have very different consequences depending on cell type, brain region, and biological context. An accompanying manuscript titled "Genome-scale functional mapping of the mammalian whole brain with in vivo Perturb-seq" is available in biorxiv and the dataset is accessible through PerturbAI's blog , Hugging Face and the NVIDIA AI Blueprint for Single-Cell Analysis.

The rich representation of cell states and causal responses in this atlas makes it a powerful AI-training resource, enabling prediction across diverse cellular contexts and unlocking key insights that could dramatically accelerate the development of biological foundation models.

PerturbAI closed an oversubscribed pre-seed round in Q3 2025, backed by leading early-stage investors with deep expertise across AI, biology, and company-building.

About PerturbAI
PerturbAI is an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases. By combining scalable in vivo CRISPR perturbation with AI, PerturbAI maps biological circuits directly inside intact organisms, enabling a new generation of therapeutics grounded in causal, in vivo biology. Visit www.perturb.ai for more information.

View original content:https://www.prnewswire.com/news-releases/perturbai-launches-from-stealth-unveils-the-worlds-largest-in-vivo-crispr-atlas-302715616.html

SOURCE PerturbAI

FAQ

What is PerturbAI's 8 million-cell CRISPR atlas and why does it matter for investors in TXG?

It is an in vivo brain-wide dataset mapping thousands of perturbations across 8 million cells, enabling causal genomics. According to PerturbAI, the atlas provides organism-level, circuit-resolved data that can accelerate AI-driven therapeutic discovery and create rich training data for biological foundation models.

How did PerturbAI generate the atlas with 10x Genomics (TXG) and partners?

PerturbAI collaborated with NVIDIA, Allen Institute, and 10x Genomics to generate and analyze the dataset. According to PerturbAI, the partners contributed technology and analysis pipelines to map perturbation effects across hundreds of neuronal cell types in mouse brain.

Does the PerturbAI atlas include human data or only mouse brain data relevant to TXG stakeholders?

The announcement describes mapping in the mouse brain across hundreds of neuronal cell types, not human tissue. According to PerturbAI, the resource is organism-level, in vivo data useful for modelling but derived from mouse brain experiments.

How can the PerturbAI atlas affect development of AI-driven therapeutics linked to TXG technologies?

The atlas supplies diverse, causal single-cell responses that can train predictive AI models across contexts. According to PerturbAI, this rich representation aims to improve translatability and efficiency of therapeutic discovery using single-cell technologies like those from TXG.

What did PerturbAI disclose about its financing and timing relevant to TXG investors?

PerturbAI said it closed an oversubscribed pre-seed round in Q3 2025. According to PerturbAI, early-stage funding from investors with AI and biology expertise supports platform development but no funding amount was disclosed.

Where can researchers and investors access the PerturbAI CRISPR atlas and manuscript?

The dataset and manuscript are publicly available through PerturbAI's blog, Hugging Face, and the NVIDIA AI Blueprint for Single-Cell Analysis. According to PerturbAI, the manuscript is posted on bioRxiv and the data is openly accessible for analysis.